Debalina Bose

Dr. Debalina Bose

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2024 in Food Bioscience
Verified
Journal Article
Closed access
DBDebalina Bose
Debalina Bose
PMPadmavati Manchikanti
Padmavati Manchikanti

20 August 2024 in Journal of Xenobiotics
Verified
Journal Article
Open access
PDF file
DBDebalina Bose
Debalina Bose
Ademola C. FamurewaAdemola C. Famurewa
Ademola C. Famurewa
AAAman Akash
Aman Akash
Eman M. OthmanEman M. Othman
Eman M. Othman
Within the domain of conventional oncochemotherapeutics, anticancer chemotherapy (AC) has emerged as a potent strategy for the treatment of cancers. AC is the mainstay strategy for solid and non-solid cancer treatment. Its mechanistic action targets the blockage of DNA transcription and the dysregulation of cell cycle machinery in cancer cells, leading to the activation of death pathways. However, the attendant side effect of toxicity inflicted by AC on healthy tissues presents a formidable challenge. The crucial culprit in the AC side effect of toxicity is unknown, although oxidative stress, mitochondrial impairment, inflammatory cascades, autophagy dysregulation, apoptosis, and certain aberrant signaling have been implicated. Honey is a natural bee product with significant health benefits and pharmacological properties. Interestingly, the literature reports that honey may proffer a protection mechanism for delicate tissue/organs against the side effect of toxicity from AC. Thus, this review delves into the prospective role of honey as an alleviator of the AC side effect of toxicity; it provides an elucidation of the mechanisms of AC toxicity and honey’s molecular mechanisms of mitigation. The review endeavors to unravel the specific molecular cascades by which honey orchestrates its mitigating effects, with the overarching objective of refining its application as an adjuvant natural product. Honey supplementation prevents AC toxicity via the inhibition of oxidative stress, NF-κB-mediated inflammation, and caspase-dependent apoptosis cascades. Although there is a need for increased mechanistic studies, honey is a natural product that could mitigate the various toxicities induced by AC.

27 October 2025 in Hematology Reports
Verified
Journal Article
Open access
PDF file
MGMina Y. George
Mina Y. George
NGNada Khaled Gamal
Nada Khaled Gamal
DMDaniel Mansour
Daniel Mansour
Ademola C. FamurewaAdemola C. Famurewa
Ademola C. Famurewa
DBDebalina Bose
Debalina Bose
Claudio CerchioneClaudio Cerchione
Claudio Cerchione
Multiple myeloma is a hematological cancer depicted by the proliferation of plasma cells within the bone marrow, causing immune dysfunction and other abnormalities. The gut microbiome, the microbial community in the gastrointestinal tract, was found to modulate systemic immunity, inflammation, and metabolism. Although the interplay between gut microbiome and multiple myeloma has been found in recent research, there is a gap in knowledge linking the effect of the microbiome on the pathogenesis and treatment of multiple myeloma. The imbalance in the gut microbiome, dysbiosis, may influence multiple myeloma pathogenesis through immune modulation and inflammation. Certain microbial species have been associated with multiple myeloma progression, complications, and therapeutic responses to treatment. Moreover, microbiome-derived metabolites, short-chain fatty acids, can influence the immune circuits associated with multiple myeloma progression. Understanding the bidirectional relationship between multiple myeloma and gut microbiota may provide insights into enhanced treatment and the development of new microbiome-based interventions. The current review provides a comprehensive highlight of current evidence linking the gut microbiome with multiple myeloma, demonstrating its significant roles in the development, progression, and treatment of multiple myeloma. Additionally, it focuses on the therapeutic potential of modulating the gut microbiome as a novel adjunct strategy in multiple myeloma management.

5 August 2025 in Journal of Xenobiotics
Verified
Journal Article
Open access
PDF file
DBDebalina Bose
Debalina Bose
AOAdetayo Olorunlana
Adetayo Olorunlana
RARania Abdel-Latif
Rania Abdel-Latif
Ademola C. FamurewaAdemola C. Famurewa
Ademola C. Famurewa
Eman M. OthmanEman M. Othman
Eman M. Othman
Virgin coconut oil (VCO) has emerged as a functional food oil with considerable health benefits and wide applications in the food, pharmaceutical, and cosmetic industries due to its resident bioactive compounds, including lauric acid (LA). LA is the most abundant saturated medium-chain fatty acid in VCO and has been associated with several pharmacological activities. The literatures show the pharmacological effects of VCO and LA on chronic pathologies, infectious diseases, and metabolic disorders. A robust body of evidence shows that LA and other phenolic compounds are responsible for the VCO protection against toxicities and pharmacological efficacies. This review elucidates the anticancer mechanisms of VCO/LA and their modulation of the chemotherapy-induced side effect toxicity. VCO, LA, and their nanomaterial/encapsulated derivatives promote ROS generation, antiproliferation, apoptosis, cell cycle arrest, the inhibition of metastasis, and the modulation of cancer-related signaling pathways for cancer cell death in vivo and in vitro. VCO mitigates oxidative inflammation and apoptosis to block the underlying mechanisms of the side effect toxicity of chemotherapy. However, the possible beneficial effect of LA on the toxicity of chemotherapy is currently unknown. The available evidence emphasizes the anticancer effect and mechanism of VCO and LA, and the VCO potential to combat adverse side effects of chemotherapy. Thus, VCO and LA are potential adjuvant therapeutic agents in the management of various cancers. Nevertheless, future studies should be targeted at elucidating cancer-related molecular mechanisms to bridge the gap in knowledge.

7 April 2026 in Phytochemistry Reviews
Verified
Journal Article
Open access
PDF file
DBDebalina Bose
Debalina Bose
GTGoutam Thakur
Goutam Thakur
CCChinthana Chidananda
Chinthana Chidananda
Curcumin, a bioactive compound in turmeric, has garnered considerable interest for its extensive bioactive potential. In addition to its well-documented anti-inflammatory, anticancer, antioxidant, and antimicrobial properties, curcumin has shown promise in wound healing. However, its low bioavailability, limited retention at the wound site, and fast metabolic breakdown have hindered its therapeutic use. Recent advancements in nanotechnology have addressed these challenges by developing curcumin-based nanoformulations that increase the stability, bioavailability, and therapeutic efficacy of these formulations. In wound management, both native and structurally modified curcumin have been shown to accelerate tissue regeneration and angiogenesis. Furthermore, curcumin-based nanocarriers exhibit potent antibacterial activity, contributing to improved healing outcomes. The integration of curcumin into nanotechnology-driven delivery systems has thus emerged as a promising strategy to maximize its therapeutic potential. This review synthesizes emerging evidence on how nanoformulation strategies such as polymeric nanoparticles, nanofibers, nanoemulsions, liposomes, hydrogels, and metal-curcumin complexes systematically overcome curcumin’s physicochemical constraints. Specifically, we delineate patterns in nanocarrier design that directly enhance curcumin’s therapeutic activity, including improved solubility, prolonged release kinetics, deeper skin penetration, enhanced antioxidant response, and targeted delivery for diabetic and infected wounds. By critically mapping these mechanistic improvements with evidence from clinical, in vitro, and in vivo studies, this review provides a consolidated framework that clarifies how nanocarrier engineering elevates curcumin from a biologically potent molecule to a clinically viable wound-healing agent. We further evaluate translational challenges, including large-scale fabrication, regulatory approval, and clinical validation, while emphasizing the future directions needed to optimize curcumin nanotherapeutics for routine wound-care applications.

16 December 2025 in ADMET and DMPK
Verified
Journal Article
Open access
PDF file
RKRinky Kapoor
Rinky Kapoor
DBDepti Bellani
Depti Bellani
RPRaji Patil
Raji Patil
DBDebalina Bose
Debalina Bose
MPMadhuri Pola
Madhuri Pola
DSDebraj Shome
Debraj Shome
Background and purpose: Non-scarring alopecia, principally androgenetic alopecia and alopecia areata is highly prevalent and psychologically burdensome; androgenetic alopecia is androgen-driven, whereas alopecia areata is autoimmune. This review synthesizes genetic architecture and pathway biology to outline a precision framework for targeted interventions. Experimental approach: We reviewed full-text studies from the past decade across PubMed, Web of Science and Google Scholar, applying explicit inclusion/ex­clusion criteria; emphasis was placed on Genome wide association studies and Next generation sequencing findings, immune and androgen-axis biology, environmental modifiers, and therapeutic evidence (conven­tional, targeted, and regenerative), alongside artificial Intelligence-enabled diagnostics. Key results: Andro­genetic alopecia risk converges on androgen-receptor signalling and related loci, with perifollicular inflam­mation and oxidative stress as modifiers; finasteride remains a cornerstone therapy. Alopecia areata reflects polygenic immune dysregulation (e.g. Human leukocyte antigen/cytokine axes) with Janus Kinase-pathway inhibition yielding robust regrowth; across phenotypes, wingless-related integration sit/β-catenin and stem-cell programs are central targets. Regenerative options (Protein Rich Plasma, stem-cell/exosome appro­aches) and artificial Intelligence-assisted stratification are emerging adjuncts. Conclusion: A pathway-guided, genotype and phenotype-informed strategy, targeting the androgen axis for androgenetic alopecia, immune circuits for alopecia areata, and adding regenerative or microenvironmental therapies where indicated-promises earlier diagnosis and more durable, individualized outcomes, especially as genome-wide association study/next-generation sequencing and artificial Intelligence tools are integrated into care.